CancerVAX, Inc. is developing immunotherapy cancer treatments that use the body’s immune system to fight cancer.
Much like COVID-19 vaccines that train the body to recognize and destroy the coronavirus, we are developing cancer vaccines that train the body to target and destroy cancer cells. Our immunotherapy platform is aimed at creating lower cost personalized CAR T-cell therapies as well as generalized antibody treatments through nanotechnology and gene-editing innovations. Our initial drug development is targeted at treating Ewing Sarcoma, a rare but deadly bone and soft tissue cancer that primarily affects children and young adults. There is currently no FDA approved treatment to prevent recurrence.
Our research is performed at the UCLA Jonsson Comprehensive Cancer Center center by a leading cancer research team. We believe the resulting immunotherapy platform will be able to target other cancers such as adrenal cancer and brain cancer, as well as enabling the development of other vaccines and drugs.
We have entered into a sponsored research agreement (SRA) with the University of California at Los Angeles (UCLA). During the term of SRA, we have the exclusive right to negotiate and license any resulting intellectual property.
We have also entered into a Letter of Intent with UCLA that gives us the exclusive right to negotiate a license to the pre-existing patent application “Methods of Treating Ewing Sarcoma.”